Cardiac hypertrophy and its resultant heart failure are among the most common causes of mortality worldwide. Abnormal protein degradation, especially the impaired lysosomal degradation of large organelles and membrane proteins, is involved in the progression of cardiac hypertrophy. However, the underlying mechanisms have not been fully elucidated.
C
ardiac hypertrophy compensates for an increase in the work demands of the heart caused by various biomechanical and pathophysiological stimuli. 1 However, long-term exposure to stress causes pathological cardiac remodeling and subsequent heart failure; these changes are pathologically characterized by irreversible cardiomyocyte enlargement, sarcomere disarrangement, myocardial fibrosis, and inflammatory infiltration. 2, 3 Although the molecular mechanisms have been studied at multiple levels, feasible targets for preventing or reversing the progression of cardiac hypertrophy are scarce.
At the cellular level, the accumulation of protein in hypertrophic cardiomyocytes is associated with both augmented protein synthesis 4, 5 and impaired protein degradation. [6] [7] [8] [9] The latter includes 2 canonical pathways: the proteasome-mediated and the lysosomemediated protein degradation pathways. 10 The proteasome digests selected individual proteins, whereas the lysosome is required to degrade large cellular components; this lysosomal process is called autophagy. 11 The lysosome is also crucial for recycling membrane proteins such as Toll-like receptor 4 (TLR4), a proinflammatory and prohypertrophy factor. 12 The recycling of membrane proteins involves the formation of multivesicular bodies (MVBs); in this process, the limiting membrane of the organelle buds toward the lumen to generate intraluminal vesicles into which specific proteins are sorted. 13, 14 The machinery involved in MVB biogenesis, the so-called ESCRT (endosomal sorting complexes required for transport) complexes, consists of 5 distinct, evolutionarily conserved complexes (ESCRT-0, ESCRT-I, ESCRT-II, ESCRT-III, and the Vps4 complex) that carry out pipeline tasks ranging from interacting with ubiquitinated membrane proteins to membrane deformation and abscission. 13, 14 After formation, a MVB can enter 2 distinct pathways: It can either fuse with the plasma membrane to secrete exosomes or fuse with the lysosome for degradation. The fate of MVBs is governed by a key factor of the ESCRT-I complex, tumor susceptibility gene 101 (TSG101). [15] [16] [17] [18] [19] However, little is known about the role of the ESCRT cascade in pathogenesisrelated signal transduction during cardiac hypertrophy.
Transmembrane BAX inhibitor motif containing 1 (TMBIM1; also called RECS1) is a membrane protein that is located in late endosomes/lysosomes. 20, 21 The functions of TMBIM1 include the inhibition of Fasmediated apoptosis, maintenance of cellular Ca 2+ homeostasis, and suppression of matrix metalloproteinase-9 production. 21, 22 Mice lacking Tmbim1 are prone to cystic medial degeneration disease and exacerbate steatohepatitis and metabolic disorders induced by a high-fat diet. 21, 23 Among the 6 TMBIM family members, TMBIM1 is enriched specifically in muscle cells and has been shown to be involved in heart failure. 20, 24 However, the molecular mechanism of TMBIM1 and its role in heart failure remain to be elucidated. Here, we identified TMBIM1 as an important regulator of cardiac hypertrophy because TMBIM1 expression levels were substantially decreased in both clinical and experimental hypertrophic hearts. The cardiac hypertrophic pathology induced by aortic banding (AB) was aggravated in Tmbim1 knockout mice but was substantially blunted in Tmbim1 transgenic mice. Mechanistically, TMBIM1 interacted directly with TSG101 via a PTAP motif and accelerated the formation of MVBs to degrade activated TLR4. TLR4 degradation is essential for the progression of cardiac hypertrophy. Expressing TMBIM1 in monkeys via lentivirus protected their hearts from AB-induced cardiac hypertrophy. These findings shed light on the role of vesicle trafficking in signaling regulation during cardiac hypertrophy and provide novel therapeutic targets for treating cardiac hypertrophy.
Clinical Perspective
What Is New?
• Cardiac transmembrane BAX inhibitor motif containing 1 (TMBIM1) is protective against aortic banding-induced cardiac hypertrophy.
• The protective effect of TMBIM1 on pathological cardiac hypertrophy is dependent on Toll-like receptor 4 (TLR4) signaling.
• TMBIM1 exerts its protective function by promoting the lysosome-mediated degradation of activated TLR4.
• TMBIM1 directly interacts with tumor susceptibility gene 101 via a PTAP motif and accelerates the formation of multivesicular bodies that deliver TLR4 to the lysosomes.
• Lentivirus-mediated TMBIM1 overexpression protects against aortic banding-induced cardiac hypertrophy in monkeys.
What Are the Clinical Implications?
• Deciphering the mechanism underlying the pathogenesis of pathological cardiac hypertrophy is crucial for developing new therapeutic strategies for heart failure resulting from prolonged cardiac hypertrophy.
• Vesicle trafficking plays an essential role in the signaling regulation of pathological cardiac hypertrophy.
• TMBIM1 acts as a multivesicular body regulator and protects against pathological cardiac hypertrophy through promoting the lysosomal degradation of TLR4.
• Targeting TMBIM1-TLR4 axis could be a novel therapeutic strategy for treating cardiac hypertrophy and heart failure.
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METHODS
A detailed description of our methods is provided in the online-only Data Supplement. The data, analytic methods, and study materials will be made available to other researchers for purposes of reproducing the results or replicating the procedure via email contact with the corresponding author.
Human Heart Samples
Left ventricular tissues of failing human hearts were obtained from patients with end-stage heart failure during heart transplantation. 25, 26 Normal heart specimens were procured from donors who died in accidents whose hearts were unsuitable for transplantation for noncardiac reasons. Before heart tissue collection, informed consent was obtained from the prospective donors. All procedures involving human samples conformed to the principles outlined in the Declaration of Helsinki and were approved by the ethics review committee of Renmin Hospital of Wuhan University.
Genetically Engineered Mice
All animal protocols were reviewed and approved by the Institutional Animal Care and Use Committee of the Animal Experiment Center/Animal Biosafety Level-III Laboratory of Wuhan University and were performed in accordance with the criteria of the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health.
Tmbim1 global knockout mice (C57BL/6 background) were obtained from RIKEN BioResource Center (Tsukuba, Ibaraki, Japan; RBRC01773).
We used a method based on the Cre/loxP recombination system to generate Tmbim1-CKO (cardiomyocyte-specific Tmbim1 knockout) and Tlr4-CKO (cardiac-specific Tlr4 knockout) mice.
27
Tmbim1
flox/flox and Tlr4 flox/flox mice were bred with the transgenic mice expressing a tamoxifen-inducible Cre-mediated recombinase driven by the cardiomyocyte-specific α-myosin heavy chain promoter (α-MHC-MCM; Jackson Laboratory) to generate Tmbim1-CTG mice (transgenic mice with cardiac-restricted overexpression of Tmbim1) were generated with the following procedure: The transgene vector that contains a CAG promoterloxP-CAT-loxP-Tmbim1 region was constructed from pCAG-loxP-CAT-loxp-lacZ by replacing the lacZ gene with full-length Tmbim1 cDNA. Subsequently, the vector was linearized and microinjected into fertilized mouse embryos (C57BL/6J background). The obtained mice were then crossed with α-MHC-MCM mice. To achieve cardiac-specific Tmbim1 overexpression, 6-weekold CAG-CAT-Tmbim1/α-MHC-MCM mice were injected with tamoxifen (T5648, Sigma-Aldrich; 25 mg/kg per day) for 5 consecutive days to induce Cre-mediated CAT gene excision.
AB Surgery in Mice
A mouse model of pressure overload-induced cardiac hypertrophy was established by AB surgery as previously described.
27
Cynomolgus Monkey Husbandry
The experimental protocols involving cynomolgus monkeys (Macaca fascicularis) were performed as previously described. 27, 28 The research protocols complied with the legal and regulatory requirements of the People's Republic of China and were approved by the Department of Forestry of Hubei Province in China. All monkey experiments adhered to the experimental animal ethics review granted by the Institutional Animal Care and Use Committee of Animal Experiment Center/Animal Biosafety Level-III Laboratory of Wuhan University.
Lentivirus Infection and AB Surgery in Monkeys
To achieve TMBIM1 overexpression in the hearts of monkeys, a lentivirus carrying the human TMBIM1-coding gene (lenti-TMBIM1) was constructed, and a lentivirus encoding green fluorescent protein (Gfp) was used as a control (lenti-vector). Lentivirus infection and AB surgery in monkeys were performed as previously described.
27,28
Echocardiographic Analyses
Echocardiographic measurements in mice were performed at the indicated times after sham or AB surgery to evaluate mouse cardiac structure and function, as previously described. 25 Echocardiography measurements in monkeys were performed on a Vivi7 Ultrasonic Doppler System (GE Healthcare) equipped with an 8-MHz 10S probe (GE Healthcare).
27,28
Histological Analyses
The heart sections of monkeys and mice were subjected to hematoxylin and eosin staining for morphological analyses and/or picrosirius red staining for collagen deposition assessments. FITC-conjugated wheat germ agglutinin (Invitrogen) staining was performed to demarcate cell boundaries, and DAPI was used to label the nuclei.
Immunostaining Analyses
After a 5-minute high-pressure antigen retrieval process in citrate buffer with a pH of 6.0, the human and mouse heart sections were blocked with BSA for 60 minutes and then incubated overnight at 4°C with TMBIM1 and cardiac troponin T antibodies. Binding was visualized with the appropriate secondary antibodies for 60 minutes at 37°C.
Primary Neonatal Rat Ventricular Myocyte Culture, Adenovirus Infection, and Immunofluorescence Staining
Primary neonatal rat ventricular myocytes (NRVMs) were isolated from 1-to 2-day-old Sprague-Dawley rat hearts and seeded in the culture plates. NRVMs were infected with the corresponding adenoviruses at a multiplicity of infection of 100 for 24 hours. Then, the cells were serum deprived for 12 hours and treated with angiotensin II (Ang II; 1 μmol/L). Transient transfection of small interfering RNA targeting Tlr4 (siTlr4) in cardiomyocytes was performed with Lipofectamine RNAiMAX (Invitrogen) to knock down Tlr4 according to the manufacturer's instructions. A specific TLR4 inhibitor, TAK-242 (tlrl-cli95, InvivoGen, 2 μmol/L), was used to suppress TLR4 signaling. To evaluate NRVM cell surface area, we performed immunofluorescence staining as previously described.
27
Microarray Performance and Analysis
To investigate the molecular mechanism underlying the regulatory role of Tmbim1 in cardiac hypertrophy, RNA extracted from the hearts of Tmbim1-Flox (n=3) and Tmbim1-CKO (n=3) mice 2 weeks after AB surgery was subjected to a microarray analysis with the Mouse Genome 430 2.0 Array (Affymetrix). The microarray data have been deposited in the National Center for Biotechnology Information Gene Expression Omnibus and are accessible through GEO Series accession number GSE96038.
For the microarray analysis, R package and Bioconductor were used. The raw data were normalized by RMA. The differentially expressed genes were identified with the limma R package with cutoff values of fold change >1.5 and P<0.05. For Kyoto Encyclopedia of Genes and Genomes (http://www. kegg.jp, Tokyo, Japan) analysis, the clusterProfiler R package was used. Gene expression was normalized by a z score normalization method. The normalized expression of the differentially expressed genes was used to generate the heat map. Figure 1 . Transmembrane BAX inhibitor motif containing 1 (TMBIM1) expression is reduced in heart failure. A, Quantitative polymerase chain reaction analyses of the mRNA levels of Tmbim1 in human heart samples from normal control donors (NF; n=6) and patients with heart failure (HF; n=6). B, Representative Western blots and quantification showing TMBIM1 and ANP (atrial natriuretic peptide) expression levels in heart samples from normal NF hearts (n=5) and HF hearts (n=8). C, Relative mRNA levels of Tmbim1 in mouse heart samples at 4 or 8 weeks after sham operations or aortic banding (AB) surgery. n=6 mice per group. D, Immunoblot analyses and quantification of TMBIM1 and ANP protein levels in the hearts of sham-operated controls and AB-induced cardiac hypertrophic mice at the indicated times. n=6 mice per group. E, Representative immunofluorescence images of cardiac troponin T (cTnT) and TMBIM1 staining in heart sections from wild-type mice. Scale bar, 20 μm. F, Representative immunofluorescence images of cTnT and TMBIM1 staining in AB-induced mouse hypertrophic hearts and the sham-operated control hearts. Scale bar, 20 μm. G, Representative immunofluorescence images of cTnT and TMBIM1 staining in the hearts of normal donors and patients with heart failure. Scale bar, 20 μm. For all statistical plots, the data are presented as mean±SD. *P<0.05, **P<0.01, ***P<0.001 between the 2 indicated groups by 2-tailed Student t test (A and B) or 1-way ANOVA with Bonferroni (C) or Tamhane T2 post hoc analysis (D). 
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Cell Lines and Treatment
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Construction of the Lentiviral Vectors Used in Cell Culture
To overexpress the wild-type and mutated TMBIM1 in H9C2 cells, the full-length or mutated Tmbim1 gene was placed into a replication-defective lentiviral vector under the control of the cytomegalovirus promoter. To stably knock down Tmbim1 in H9C2 cells, shRNAs targeting Tmbim1 were cloned into the pLKO.1 lentiviral vector (No. 10878, Addgene), and an shRNA targeting Gfp was used as a control.
Plasmid Construction
The full-length and truncated Flag-TMBIM1 plasmids were obtained by cloning the cDNA of Tmbim1 into the CAG-Flag vector. The full-length and truncated HA-TSG101 plasmids were obtained by cloning the indicated cDNA of Tsg101 into the pcDNA3.1-HA vector.
Immunoprecipitation Assay
Immunoprecipitation assays involving full-length/truncated TMBIM1 and TSG101 were performed as previously described.
25
Immunofluorescence Staining in H9C2 Cells
H9C2 cells infected with Cherry-TMBIM1/TMBIM1
ΔPTAP lentivirus were treated with 4% paraformaldehyde followed by permeabilization with 0.1% saponin and then incubated with rabbit anti-lysosomal associated membrane protein 2 (No. L0668, 1:50 dilution, Sigma). The cells were then incubated with an Alexa Fluor 488-conjugated donkey anti-rabbit IgG (A21206, 1:500 dilution, Invitrogen) secondary antibody and observed by confocal microscopy (LCS-SP8-STED, Leica).
Quantitative Real-Time Polymerase Chain Reaction
Real-time polymerase chain reaction was performed as previously described. 25 The real-time polymerase chain reaction primer pairs used in this study are listed in the Table I in the online-only Data Supplement.
Western Blot Assay
Western blot was performed as previously described. 27 The expression levels of specific proteins were normalized to that of GAPDH. For immunoprecipitated samples, Clean-Blot IP Detection Reagent (21230, Thermo Fisher Scientific) was used.
Statistical Analysis
Statistical analyses were performed with the SPSS software (version 19.0). For data with gaussian distribution, parametric statistical analysis was performed with the 2-tailed Student t test for 2 groups; 1-way ANOVA was applied for multiple comparisons with Bonferroni post hoc analysis for data meeting homogeneity of variance or with the Tamhane T2 analysis for data of heteroscedasticity. For data sets with skewed distribution, nonparametric statistical analysis was performed with the MannWhitney U test for 2 groups; the Kruskal-Wallis test was used for multiple comparisons. Only in the cases in which the global null hypothesis was rejected was pairwise comparison then performed. All values are presented as the mean±SD. P values were specified as follows: *P<0.05, **P<0.01, and ***P<0.001.
RESULTS
TMBIM1 Expression Is Decreased in Cardiac Hypertrophy
To study the role of TMBIM1 in the development of heart failure, we examined the mRNA and protein levels of TMBIM1 in failing human hearts by quantitative polymerase chain reaction and Western blot analyses. In contrast to the marked upregulation of the pathological marker gene ANP (atrial natriuretic peptide), the failing hearts expressed lower TMBIM1 mRNA and protein levels than the nonfailing hearts ( Figure 1A and 1B and Table II in the online-only Data Supplement). These results are consistent with a progressive decrease in TMBIM1 expression levels in mice at 4 and 8 weeks after cardiac hypertrophy was induced by AB ( Figure 1C and 1D ). Immunofluorescence staining of the mouse heart tissues showed that TMBIM1 was expressed predominantly in cardiomyocytes, as indicated by its colocalization with cardiac troponin T ( Figure 1E-1G ). The intensity of the TMBIM1 signal in cardiomyocytes was substantially reduced in hypertrophic hearts from AB-challenged mice and patients with dilated cardiomyopathy compared with hearts from sham or normal controls ( Figure 1F and 1G). These results imply a potential role for TMBIM1 in the progression of cardiac hypertrophy. 
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Tmbim1 Deletion Exacerbates the Pathology of Cardiac Hypertrophy
To evaluate the impact of TMBIM1 on cardiac hypertrophy, we used Tmbim1 whole-body knockout mice ( Figure  Ia in the online-only Data Supplement). These mice and their age-matched wild-type littermates were challenged with AB surgery. Although no remarkable changes were observed at the basal level, Tmbim1 deficiency significantly increased the heart weights and heart sizes after AB surgery ( Figure Ib 
TMBIM1 Alleviates Cardiac Hypertrophy In Vitro
To validate that cardiomyocytes act as both the source and the target of functional TMBIM1, we measured TMBIM1 expression in isolated neonatal rat ventricular myocytes (NRVMs) treated with angiotensin II (Ang II; 1 μmol/L). We found that TMBIM1 protein levels were significantly reduced in Ang II-treated NRVMs (Figure 2A ). We then manipulated Tmbim1 expression by adenovirus-mediated transgene expression of a Tmbim1-specific shRNA (AdshTmbim1; Figure 2B ) and wild-type Tmbim1 (AdTmbim1; Figure 2B ) with or without hypertrophic stimulation. Ang II-induced cardiomyocyte hypertrophy was markedly exacerbated by Tmbim1 knockdown but was significantly suppressed by Tmbim1 overexpression compared with the respective controls (scramble shRNA and AdVector; Figure 2C and 2E) . Consistently, the AB-induced expression of the marker genes Anp and Myh7 was potentiated by Tmbim1 knockdown but was reversed by Tmbim1 overexpression ( Figure 2D and 2F ). These data suggest that TM-BIM1 plays a protective role in cardiac hypertrophy in vitro.
Cardiac TMBIM1 Protects Against Hypertrophy In Vivo
To confirm the physiological function of cardiac TM-BIM1 in vivo, we then generated Tmbim1-CKO mice and Tmbim1-CTG mice ( Figure IIa and IIb in the onlineonly Data Supplement). Tmbim1 knockdown and overexpression in the heart were both verified by Western blots and immunohistochemistry staining ( Figure IIc -IIe in the online-only Data Supplement). Neither Tmbim1-CKO mice nor Tmbim1-CTG mice showed cardiac phenotypic differences at the basal level. However, the survival rate was significantly decreased in Tmbim1-CKO mice after AB surgery compared with the α-MHC-MCM and Tmbim1-Flox controls ( Figure IIf in the online-only Data Supplement). In addition, Tmbim1-CKO mice substantially exacerbated the AB-induced hypertrophic pathology as shown by the heart weight/body weight ratio ( Figure 3A ), heart size ( Figure 3B ), lung weight/body weight ratio ( Figure IIg in the online-only Data Supplement), left ventricular end-diastolic diameter ( Figure 3C and Table IV in the online-only Data Supplement), LVFS ( Figure 3C and Table IV in 
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ure IIi through IIk and Table V in the online-only Data Supplement). These results strongly support the view that cardiac TMBIM1 protects the heart from pathological remodeling in AB-induced hypertrophy.
TMBIM1 Functions Through the TLR4 Signaling Pathway
To explore the mechanism underlying the protective effects of TMBIM1, we performed a microarray analysis to profile the transcriptomic differences between the hearts from Tmbim1-Flox and Tmbim1-CKO mice. After gene selection based on fold changes (>1.5) and P values (<0.05), we found that 132 genes were upregulated and that 124 genes were downregulated in Tmbim1-CKO hearts compared with Tmbim1-Flox controls ( Figure 4A) . A functional clustering analysis highlighted that the TLR signaling pathway was highly affected ( Figure 4B and 4C). Among the TLRs, TLR4 is highly expressed in the heart and involved in the pathogenesis of cardiac hypertrophy. 29, 30 In addition, deregulated genes that were downstream of TLR4 were apparent among the TLR signaling pathways ( Figure III in the online-only Data Supplement). We thus evaluated the expression levels of TLR4 in hypertrophic hearts from Tmbim1-CKO and Tmbim1-CTG mice. Although the Tlr4 mRNA levels were increased in response to AB surgery, they were not significantly affected by either Tmbim1 deficiency or Tmbim1 overexpression ( Figure 4D) . Nevertheless, the increased protein levels of TLR4 after AB surgery were further elevated in Tmbim1-CKO mice but were blunted in Tmbim1-CTG mice ( Figure 4E ). These results suggest that TMBIM1 regulates TLR4 protein degradation.
To validate the in vivo observations, isolated NRVMs were infected with adenoviruses expressing shTmbim1 or Tmbim1 and were treated with Ang II or without Ang II. Western blot analyses demonstrated that the downstream cascades of the TLR4, mitogen-activated protein kinase (phosphorylated extracellular signal-regulated kinase, phosphorylated c-Jun N-terminal kinase, and phosphorylated p38), and nuclear factor-κB (phosphorylated p65) signaling pathways were activated by Ang II ( Figure 4F and 4G) ; moreover, Ang II-induced TLR4 signaling was potentiated by Tmbim1 knockdown but suppressed by Tmbim1 overexpression compared with the corresponding controls ( Figure 4F and 4G) . In addition, we treated H9C2 cells with lipopolysaccharide, an activator of TLR4, 12, 31 and observed similar results (Figure IVa and IVb in the online-only Data Supplement). To further confirm that the regulatory effects of TMBIM1 on pathological cardiac hypertrophy were TLR4 dependent, we performed Tlr4 knockdown experiments using siRNA targeting Tlr4 in NRVMs ( Figure IVc in the online-only Data Supplement). Our results indicated that the excessively activated mitogen-activated protein kinase and nuclear factor-κB signaling after Tmbim1 knockdown was abolished by siTlr4 ( Figure 4H ). These effects reversed the cell size enlargement and reduced the pathological gene expression levels induced by Tmbim1 deficiency (Figure 4I and 4J) . Moreover, we examined the impact of a specific TLR4 inhibitor, TAK-242 (2 μmol/L), on Ang II-induced hypertrophy in NRVMs with or without Tmbim1 knockdown. The results showed that TAK-242 significantly reversed the cardiomyocyte hypertrophic response caused by Tmbim1 silencing (Figure IVd and IVe in the online-only Data Supplement).
We next assessed whether disrupting TLR4 could rescue the detrimental effects of Tmbim1 knockout on cardiac hypertrophy in vivo. We generated a Tlr4 flox/flox (Tlr4-Flox) mouse line that was crossed with α-MHC-MCM mice followed by tamoxifen treatment to produce mice with cardiac-specific Tlr4 knockout ( Figure V in the online-only Data Supplement). We also produced cardiac-specific Tmbim1 and Tlr4 double-knockout mice. Individual or double knockout of Tmbim1 and Tlr4 was confirmed in the hearts from mice with different genotypes ( Figure 5A ). Cardiac Tlr4 knockout on the Tmbim1-CKO background significantly reversed the hypertrophic pathology induced by AB surgery, as shown by the heart weight/body weight ratio ( Figure 5B ), heart size (Figure 5C ), left ventricular end-diastolic diameter ( Figure 5D and Table VI in the online-only Data Supplement), LVFS ( Figure 5D and Table VI in the online-only Data Supplement), cardiomyocyte cross-sectional area ( Figure 5E ), myocardial fibrosis ( Figure 5F ), and pathological gene expression ( Figure 5G ). These results suggest that TMBIM1 regulates TLR4 activity to affect cardiac hypertrophy.
TMBIM1 Promotes the Lysosomal Degradation of TLR4
The fact that TMBIM1 regulates TLR4 at the protein level but not the mRNA level suggests that protein degradation is involved. In H9C2 cells, fluorescent imaging revealed that TMBIM1 colocalized with TLR4 and the late endosome/lysosome marker protein lysosomal associated membrane protein 2 ( Figure 6A ). We then hypothesized that TMBIM1 might facilitate the lysosomal degradation of activated TLR4. To validate this hypothesis, we treated H9C2 cells with lipopolysaccharide and assessed the im- pact of Tmbim1 overexpression using lentivirus infection. We found that TMBIM1 promoted the degradation of TLR4 in lipopolysaccharide-treated H9C2 cells in the presence of cycloheximide (20 μg/mL). This effect was abolished by a lysosome inhibitor, chloroquine (25 μmol/L), but not by a proteasome inhibitor, MG132 (10 μmol/L; Figure  VIa in the online-only Data Supplement). Moreover, we found that in NRVMs, Ang II treatment triggered the degradation of TLR4 in a chloroquine-sensitive manner; this degradation was promoted by TMBIM1 overexpression ( Figure 6B ). To further elucidate the dynamic processing involved, we stimulated H9C2 cells with lipopolysaccharideCy5 to evaluate TLR4 trafficking. 12, 31 Lysotracker probes were used to label late endosomes and lysosomes. The distribution of internalized lipopolysaccharide-Cy5/TLR4 complexes was comparable in all groups after lipopolysaccharide-Cy5 stimulation for 1 hour. After stimulation for 6 hours, however, the majority of the lipopolysaccharideCy5 signal was quenched in both control and Tmbim1-overexpressing cells, but this process was substantially delayed in Tmbim1-deficient cells ( Figure 6C and 6D ). These data suggest that TMBIM1 is crucial for the lysosomal degradation of activated TLR4.
To further confirm that the TMBIM1-mediated antihypertrophic effects were dependent on TLR4 lysosomal degradation, we infected NRVMs with AdTmbim1 alone or AdTmbim1 combined with an adenovirus expressing a constitutively active form of TLR4 that lacks the extracellular domain structure. 32 The enlarged cell size and higher mRNA levels of fetal cardiac genes demonstrated that the presence of constitutive activation of TLR4 reversed the protective effects of Tmbim1 overexpression ( Figure 6E and 6F) . We also assessed the effect of chloroquine on cardiomyocyte hypertrophy by infecting NRVMs with AdTmbim1 alone or AdTmbim1 plus chloroquine (25 μmol/L) treatment followed by Ang II stimulation. We hypothesized that chloroquine treatment could suppress the lysosomal degradation of TLR4 and then reverse the alleviating effects promoted by Tmbim1 overexpression. However, chloroquine treatment showed inhibitory effects on hypertrophic response induced by Ang II, as evidenced by the alleviated cell size enlargement and pathological gene Anp expression ( Figure VIb and VIc in the online-only Data Supplement). Moreover, chloroquine treatment showed no effects on TMBIM1-mediated antihypertrophic function ( Figure VIb and VIc in the online-only Data Supplement). This may be attributed to its broad spectrum and mixed effects on TLRs, lysosome function, and autophagy. 33, 34 Taken together, our results demonstrated that TMBIM1 protects against pathological cardiac hypertrophy by promoting the lysosomal degradation of activated TLR4.
TMBIM1 Directly Interacts With TSG101 Via a PTAP Motif
MVB formation is a key step in the delivery of transmembrane proteins such as TLR4 to the lysosome for degradation.
12,13 MVB biogenesis is a step in the ESCRT pathway and is carried out by the cargo sequestering and sorting machinery.
14 Because TMBIM1 contains a PTAP motif (amino acids 4-7 in rat; referred to as PSAP in mouse) similar to that found in the TSG101-binding protein hepatocyte growth factor-regulated tyrosine kinase substrate (a component of ESCRT-0), 18 we analyzed whether TMBIM1 could interact with TSG101. Reciprocal coimmunoprecipitation experiments confirmed the interaction between TMBIM1 and TSG101 ( Figure 7A ). This interaction was validated by the colocalization of TMBIM1 and TSG101 in H9C2 cells according to confocal imaging ( Figure 7B ). To determine whether the PTAP motif was responsible for this interaction, we deleted the PTAP sequence from TMBIM1 and found that its interaction with TSG101 was abolished ( Figure 7C ). The ubiquitin E2 variant domain of TSG101 is responsible for its interaction with PTAP motif-containing targets. 35, 36 Our coimmunoprecipitation experiments showed that the ubiquitin E2 variant domain of TSG101 is both necessary and sufficient for its interaction with TMBIM1 ( Figure 7D ). To determine whether the PTAP motif of TMBIM1 was necessary for its regulation of TLR4, we overexpressed mutant Tmbim1 without the PTAP motif (Tmbim1 
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Tmbim1 ΔPTAP in NRVMs by adenovirus infection and found that Tmbim1
ΔPTAP did not promote TLR4 degradation or suppress the activation of signaling downstream of TLR4 (mitogen-activated protein kinase and nuclear factor-κB) in response to Ang II treatment ( Figure 7E and 7F) . Consistently, Tmbim1
ΔPTAP failed to suppress Ang II-induced NRVMs hypertrophy; wild-type Tmbim1 overexpression did, however, suppress Ang II-induced cardiomyocytes hypertrophy ( Figure 7G and 7H) .
Expressing Human TMBIM1 in Monkeys Blocks Cardiac Hypertrophy
To evaluate the therapeutic potential of our findings, we generated a lentivirus construct expressing human TM-BIM1 and examined its effect in a monkey AB-induced cardiac hypertrophy model. The protein level of TMBIM1 in the monkey hearts increased ≈2-fold after lentivirus infection ( Figure 8A ). AB surgery significantly increased the heart weight/body weight ratio, interventricular septal thickness at end diastole, interventricular septal thickness at end systole, left ventricular posterior wall thickness at end-diastole, and left ventricular posterior wall thickness at end systole compared with the sham control group (Figure 8B and 8C) . However, the lung weight/body weight ratio, left ventricular internal diameter at end diastole, left ventricular internal diameter at end systole, left ventricular ejection fraction, and LVFS were not changed ( Figure 8B through 8D). Human TMBIM1 expression significantly reduced the heart weight gains ( Figure 8B , top) at 70 days after AB without affecting the lung weights ( Figure 8B , bottom). Echocardiography showed that human TMBIM1 significantly abrogated the increases in interventricular septal thickness at end diastole, interventricular septal thickness at end systole, left ventricular posterior wall thickness at end diastole, and left ventricular posterior wall thickness at end systole without affecting left ventricular internal diameter at end diastole and left ventricular internal diameter at end systole after AB surgery ( Figure 8C ). Although no difference was observed in cardiac contractile function as determined by left ventricular ejection fraction ( Figure 8D , top) and LVFS ( Figure 8D, bottom) , human TMBIM1 significantly reversed the enlargement of monkey cardiomyocytes ( Figure 8E and 8F) and the induced expression of ANP and MYH7 after AB ( Figure 8G ). These data strongly support the use of TMBIM1 to treat cardiac hypertrophy.
DISCUSSION
Stress response at the cellular level requires a transient brake to counteract the activated signaling and to maintain cellular homeostasis. 37 Failure of these braking systems is involved in the pathogenesis of most human diseases. Here, we describe a molecular model of cardiac hypertrophy in which TMBIM1 protects the heart by accelerating the lysosome-mediated sequestration of activated TLR4 ( Figure VIII in the online-only Data Supplement). Furthermore, the downregulation of TMBIM1 drives the overactivation of pathological signaling and the progression of cardiac hypertrophy. Although robust effects can be observed after stimulus overload, neither Tmbim1-CKO nor Tmbim1-CTG mice had altered heart functions at the basal level. These results suggest that TMBIM1 desensitizes the heart to stress without affecting the development of the heart and its normal function.
The innate immune regulatory network plays a pivotal role in the pathogenesis of cardiovascular diseases. 25, 27, [38] [39] [40] As an initiating receptor of the innate immune signaling cascade, TLR4 is upregulated in human patients and animal models of cardiac hypertrophy. 41 TLR4 also plays a critical role in mediating myocardial inflammation associated with cardiac hypertrophy. 30, 42, 43 The genetic and pharmacological inhibition of TLR4 exerts protective effects against cardiac hypertrophy in mice. 30, 42, 43 However, TLR4 can also play a beneficial role in myocardial inflammation, especially in myocarditis. 42 The direct and complete inhibition of TLR4 may impair the functional innate immune system and thus may not be a promising therapeutic option for improving the prognosis of myocardial inflammation. Here, we show that TMBIM1 negatively modulates TLR4 signaling by accelerating the lysosomal degradation of activated TLR4 in response to only pathological stimulation. This discovery provides a novel strategy for drug targeting that would not affect the physiological function of TLR4.
Lysosome-associated degradation of TLR4 involves the formation of MVBs, a process in which the ES-CRT complexes work together sequentially to mediate membrane activities. 14 Here, we found a direct interaction between TMBIM1 and the ESCRT-I component TSG101 through the PTAP motif ( Figure 7A through  7D ). This interaction promotes the lysosomal trafficking and degradation of TLR4 ( Figure 6C and 6D ). In addition, TSG101 plays an important role in exosome secretion and virus release; these processes also require MVB formation. 15 It would be interesting to further examine the potential role of TMBIM1 in regulating exosome biogenesis under disease conditions. Unlike the other ESCRT complexes, none of the ESCRT-I components contain a specific domain that exhibits a high affinity for membrane lipids. 44 Nevertheless, TMBIM1 is a membrane protein localized specifically on the endosome/lysosome membrane. Its location implies that TMBIM1 promotes membrane kinetics via the ESCRT-I complex during MVB formation and endosome maturation. It is worth further investigation to determine whether this mechanism also applies to the general recycling process of other membrane receptors under different pathological conditions. Furthermore, the TMBIM family includes 6 highly conserved members involved in diverse biological processes. The TMBIM1 
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mechanism revealed here might shed light on the roles of other family members. Expression of TMBIM1 has been found to be upregulated in responsive to shear stress in endothelial cells. 45 However, the data in our present study reveal that TMBIM1 in cardiomyocytes was significantly decreased at both the mRNA and protein levels on hypertrophic stimuli. The different pattern of TMBIM1 expression may be attributed to the difference in cell type and stimulation. Further studies are needed to uncover the transcriptional regulation of TMBIM1 in pathological cardiac hypertrophy. Previous study has identified that endothelial cell TMBIM1 is an essential mediator of vascular diseases such as atherogenesis. 45 A very recent study by our group has demonstrated that hepatocytespecific TMBIM1 protects against nonalcoholic fatty liver disease by targeting the lysosomal degradation of TLR4. 23 In our present study, we further identified that cardiomyocyte TMBIM1 exhibited a novel protective role in pathological cardiac hypertrophy through promoting the lysosomal degradation of activated TLR4. These results indicated a multifunctional role of diverse cell type-derived TMBIM1 in different disease models. Our findings revealed a similar regulatory mechanism of TLR4 in the 2 completely different cell types, which contributes to the multiple regulatory effects of TM-BIM1 on liver steatosis and cardiac hypertrophy. Further studies should ensue to investigate whether TMBIM1 shared a common regulatory mechanism of TLR4 in the pathogenesis of other diseases besides nonalcoholic fatty liver disease and pathological cardiac hypertrophy.
To investigate the clinical translation potential of TM-BIM1 for the treatment of pathological cardiac hypertrophy and heart failure, we here further verified that TMBIM1 overexpression provides significant protection against AB-induced hypertrophic pathogenesis in monkeys ( Figure 8 ). However, several limitations of our monkey experiments should be considered. In this study, sham-operated monkeys without lentivirus infection were included as the sham control group. Theoretically, shamoperated monkeys infected with lenti-vector or lenti-TMBIM1 should be included as the sham control groups. From the results of our preliminary experiments performed on pigs, we know that neither lenti-vector infection nor lenti-TMBIM1 infection affects the cardiac phenotype under the baseline. From our present results, we can confirm the success of the AB surgery by comparing the parameters of the self-controlled pre-and post-ABoperated lenti-vector groups, which is further confirmed by the comparison between the sham control without lentivirus infection (sham control pod) and AB monkeys with lenti-vector infection (lenti-vector pod). Moreover, comparison between the lenti-vector pod and lenti-TM-BIM1-infected AB monkeys (lenti-TMBIM1 pod) groups sufficiently reveals the protective effect of TMBIM1 on the pathogenesis of cardiac hypertrophy in monkeys. Furthermore, using monkey for hypertrophy studies is extremely expensive and ethically critical. Considering the 3R (reduction, replacement, and refinement) principle for animal wealth, we did not include the sham-operated monkeys with lenti-vector infection or lenti-TMBIM1 infection as the sham control groups. Another limitation that should be noted is that the type of cell in which TMBIM1 is overexpressed in our monkey heart experiments is unclear. Although the lentivirus-mediated gene overexpression approach leads to optimal expression of TMBIM1, it does not allow us to achieve cardiomyocyte-specific TMBIM1 overexpression. In this regard, the protective role of TM-BIM1 in pathological cardiac hypertrophy that we have identified in our monkey experiments reveals the universal effect of TMBIM1 in the whole heats. Nevertheless, the results of our monkey experiments positively suggest the potential clinical translation of TMBIM1 into a therapeutic target for pathological cardiac hypertrophy.
CONCLUSIONS
Our study identifies TMBIM1 as an essential negative regulator of pathological cardiac hypertrophy in mice and large primates. Moreover, our findings strongly support the view that TMBIM1, as well as the downstream lysosome-associated TLR4 degradation pathway, is a promising therapeutic strategy for the treatment of pathological cardiac hypertrophy and heart failure in the clinic. 
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